Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-DTPA-omburtamab |
| Synonyms | |
| Therapy Description |
177Lu-DTPA-omburtamab is a radioconjugate comprising an antibody targeting CD276 (B7-H3) linked to lutetium-177, which potentially inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2021; 9, Suppl 2, 397, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-DTPA-omburtamab | lutetium Lu 177-DTPA-omburtamab|[177Lu]-DTPA-omburtamab|177Lu-DTPA omburtamab | CD276 Antibody 26 | 177Lu-DTPA-omburtamab is a radioconjugate comprising an antibody targeting CD276 (B7-H3) linked to lutetium-177, which potentially inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2021; 9, Suppl 2, 397, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07698899 | Phase I | 177Lu-DTPA-omburtamab | A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) | Recruiting | USA | 0 |